Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2019 Aug 1;69(4):717-719.
doi: 10.1093/cid/ciz039.

Improved Outcomes With High-dose Isoniazid in Multidrug-resistant Tuberculosis Treatment in Haiti

Kathleen F Walsh  1 , Stalz Charles Vilbrun  2 , Ariadne Souroutzidis  3 , Sobieskye Delva  2 , Guy Joissaint  2 , Laurent Mathurin  2 , Oksana Ocheretina  1 , Pierre Cremieux  3 , Jean William Pape  2 , Serena P Koenig  4
Affiliations

Improved Outcomes With High-dose Isoniazid in Multidrug-resistant Tuberculosis Treatment in Haiti

Kathleen F Walsh et al. Clin Infect Dis. .

Abstract

We report outcomes for a cohort of patients with multidrug-resistant tuberculosis who received high-dose isoniazid in Haiti. Patients who received high-dose isoniazid had a faster time to culture conversion and higher odds of successful outcome, despite high-level isoniazid resistance. This suggests high-dose isoniazid may have effectiveness even with phenotypic resistance.

Keywords: MDR-TB; drug resistance; high-dose isoniazid; tuberculosis.

PubMed Disclaimer

Figures

Figure 1.
Figure 1.
Time to culture conversion stratified by high-dose isoniazid treatment among human immunodeficiency virus–negative patients. Abbreviation: INH, isoniazid.
See this image and copyright information in PMC

References

    1. World Health Organization. Technical report on the pharmacokinetics and pharmacodynamics (PK/PD) of medicines used in the treatment of drug-resistant tuberculosis. Geneva, Switzerland: World Health Organization, 2018.
    1. Katiyar SK, Bihari S, Prakash S, Mamtani M, Kulkarni H. A randomised controlled trial of high-dose isoniazid adjuvant therapy for multidrug-resistant tuberculosis. Int J Tuberc Lung Dis 2008; 12:139–45. - PubMed
    1. Jacobson KR, Theron D, Victor TC, Streicher EM, Warren RM, Murray MB. Treatment outcomes of isoniazid-resistant tuberculosis patients, Western Cape Province, South Africa. Clin Infect Dis 2011; 53:369–72. - PMC - PubMed
    1. Companion handbook to the WHO guidelines for the programmatic management of drug-resistant tuberculosis. Geneva, Switzerland: World Health Organization, 2014. - PubMed
    1. Rieder HL, Van Deun A. Rationale for high-dose isoniazid in the treatment of multidrug-resistant tuberculosis. Int J Tuberc Lung Dis 2017; 21:123–4. - PubMed